【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the Top Biosimilar Drug Manufacturers
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Biosimilar Drugs: World Market Forecast, 2016-2026
2.1 Introduction to Biologics and Biosimilars
2.1.1 Biologic Drugs Definition and Overview
2.1.2 Biosimilars Drugs Definition and Overview
2.1.3 How do Biosimilars Differ from Generics?
2.2 The World Biosimilar Market, 2015-2026
2.3 Overall World Biosimilars Revenue Forecast, 2016-2026
2.4 Biosimilars – Realising their Potential, Market Drivers
2.4.1 Biosimilar Approval Pathways and Regulations
2.4.2 Emerging Markets for Biosimilars
2.4.3 Start-up Pressure on Market Leaders
2.4.4 The Patent Cliff for Biologics
2.5 Biosimilars: Market Restraints
2.5.1 Market Fragmentation for Biosimilar Products
2.5.2 Innovative Biologics – Rendering Biosimilars Useless?
2.5.3 Biobetters – A Growing Threat
3. Leading Biosimilar Products: Overview, 2016
3.1 Humira: Product Overview
3.1.1 Adalimumab Biosimilars – Zydus Cadila
3.1.2 Adalimumab Biosimilars – Amgen-Actavis
3.1.3 Adalimumab Biosimilars – Sandoz
3.1.4 Adalimumab Biosimilars – Momenta Pharmaceuticals
3.1.5 Adalimumab Biosimilars – Pfizer
3.1.6 Adalimumab Biosimilars – Boehringer Ingelheim
3.2 Remicade: Product Overview
3.2.1 Infliximab Biosimilar – Epirus Pharmaceuticals & Ranbaxy
3.2.2 Infliximab Biosimilar – Celltrion & Hospira & Alvogen
3.3 Enbrel: Product Overview
3.3.1 Etanercept Biosimilar – Cipla & Shanghai CP Guojian
3.3.2 Etanercept Biosimilar – Daiichi Sankyo & Coherus Biosciences
3.4 Aranesp: Product Overview
3.4.1 Darbepoetin Alpha Biosimilar – Dr. Reddy’s Laboratories
3.4.2 Darbepoetin Alpha Biosimilar – Cipla & Hetero Drugs Limited
3.4.3 Darbepoetin Alpha Biosimilar – Hospira
3.5 Rituxan: Product Overview
3.5.1 Rituximab Biosimilar – Sandoz
3.5.2 Rituximab Biosimilar – Amgen
3.5.3 Rituximab Biosimilar – Boehringer Ingelheim
3.5.4 Rituximab Biosimilar – Dr. Reddy’s Laboratories
3.5.5 Rituximab Biosimilar – Pfizer
3.5.6 Rituximab Biosimilar – Difficulties Seen in Trials
4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2016
4.1 Sandoz – Company Overview & Analysis
4.1.1 Sandoz Biosimilar Products
4.1.2 Sandoz Biosimilars Market Forecast, 2016-2026
4.1.3 Sandoz Biosimilars R&D Pipeline & Future Outlook
4.1.3.1 GP2017 – Adalimumab Biosimilar
4.1.3.2 GP2015 – Etanercept Biosimilar
4.1.3.3 GP2013 – Rituximab Biosimilar
4.1.3.4 HX575 – Epoetin-alfa Biosimilar
4.1.3.5 EP2006 – Zarzio (Filgrastim Biosimilar)
4.2 Teva Pharmaceuticals – Company Overview & Analysis
4.2.1 Teva Biosimilar Products
4.2.2 Teva Biosimilar Market Forecast, 2016-2026
4.2.3 Teva Biosimilar Pipeline & Future Outlook
4.3 Hospira – Company Overview & Analysis
4.3.1 Hospira Biosimilar Products
4.3.2 Hospira Biosimilars Pipeline & Future Strategies
4.3.2.1 Retacrit
4.3.2.2 Celltrion Partnerships
4.3.2.3 NovaQuest Partnership
4.4 STADA Arzneimittel – Company Overview & Analysis
4.4.1 STADA Biosimilar Products
4.4.2 STADA Biosimilars Pipeline & Future Outlook
4.4.2.1 Biosimilar Pegfilgrastim
4.4.2.2 Biosimilar Rituximab
4.4.2.3 Biosimilar Teriparatide
4.5 Mylan – Company Biosimilar & Analysis
4.5.1 Mylan Biosimilar Products
4.5.2 Mylan Biosimilar Market Forecast, 2016-2026
4.5.3 Mylan Biosimilars Pipeline & Future Outlook
4.5.3.1 Mylan and Momenta – Biosimilars Product Development Programme
4.5.3.2 Biosimilar Insulin Glargine
4.5.3.3 A Series of Biosimilar Monoclonal Antibodies
4.5.3.4 Biosimilar Insulin Lispro & Aspart
4.6 Other Biosimilars Companies in the US
4.6.1 Impax Laboratories Inc. – Company Overview & Analysis
4.6.2 Bristol-Myers Squibb – Company Overview & Analysis
4.6.3 Merck & Co. – Company Overview & Analysis
4.6.4 Eli Lilly – Company Overview & Analysis
4.7 Other Biosimilars Companies in Europe
4.7.1 BioXpress Therapeutics – Company Overview & Analysis
4.7.2 Medice Arzneimittel Pütter GmbH & Co. KG – Company Overview & Analysis
4.7.3 Finox Biotech – Company Overview & Analysis
4.7.4 Actavis – Company Overview & Analysis
5. Leading Biosimilar Manufacturers in China, 2016
5.1 S3Bio – Company Overview & Analysis
5.1.1 3SBio Biosimilar Products
5.1.2 3SBio Biosimilars Market Forecast, 2016-2026
5.1.3 3SBio Biosimilars Pipeline & Future Outlook
5.1.3.1 Second-generation rhEPO products
5.1.3.2 Nadroparin Calcium
5.2 Qilu Pharmaceutical – Company Overview & Analysis
5.2.1 Qilu Pharmaceutical Biosimilar Products
5.2.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.2.2.1 Extensive Pipeline Developments
5.2.2.2 Etanercept Biosimilar
5.2.2.3 Other Biosimilars in Pipeline
5.3 Shanghai Fosun Pharmaceuticals – Company Overview & Analysis
5.3.1 Shanghai Fosun Pharmaceuticals Biosimilar Products
5.3.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy
5.3.2.1 Trastuzumab Biosimilar
5.3.2.2 Rituximab Biosimilar
5.3.2.3 Acquisitions and Investments
5.4 Tonghua Dongbao – Company Overview & Analysis
5.4.1 Tonghua Dongbao Biosimilar Products
5.4.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies
5.4.2.1 Biosimilar Insulin Analogues
5.4.2.2 Investments in New Production Plant
5.5 Beijing ShuangLu Pharmaceuticals – Company Overview & Analysis
5.5.1 Beijing ShuangLu Pharmaceuticals Biosimilar Products
5.5.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.6 Other Biosimilars Companies in China
5.6.1 Shanghai CP Guojian – Company Overview & Analysis
5.6.2 Zhejiang Hisun – Company Overview & Analysis
5.6.3 Innovent Biologics – Company Overview & Analysis
5.6.4 Shanghai Celgen Biopharmaceutical – Company Overview & Analysis
6. Leading Biosimilar Manufacturers in India, 2016
6.1 Biocon – Company Overview & Analysis
6.1.1 Biocon Biosimilar Products
6.1.2 Biocon Biosimilars Market Forecast, 2016-2026
6.1.3 Biocon Biosimilars Pipeline & Future Outlook
6.1.3.1 Biosimilar Bevacizumab
6.1.3.2 Biosimilar Adalimumab
6.1.3.3 Biosimilar Pegfilgrastim
6.1.3.4 Biosimilar Trastuzumab
6.1.3.5 Biosimilar Etanercept
6.1.3.6 Biosimilar Recombinant Human Insulin
6.1.3.7 Biosimilar Insulin Glargine
6.1.3.8 Other Biosimilar Insulin
6.2 Dr. Reddy’s Laboratories – Company Overview & Analysis
6.2.1 Dr. Reddy’s Laboratories Biosimilar Products
6.2.2 Dr. Reddy’s Laboratories Biosimilars Pipeline & Future Outlook
6.2.2.1 Merck Serono Collaboration
6.2.2.2 Increasing Focus on Emerging Markets
6.3 Wockhardt – Company Overview & Analysis
6.3.1 Wockhardt Biosimilar Products
6.3.2 Wockhardt Biosimilars Pipeline & Future Outlook
6.4 Zydus Cadila – Company Overview & Analysis
6.4.1 Zydus Cadila Biosimilar Products
6.4.2 Zydus Cadila Biosimilars Pipeline & Future Outlook
6.4.2.1 Biosimilar Interferon beta-1b
6.4.2.2 Oncology Biosimilars
6.4.2.3 Inflammation Biosimilars
6.4.2.4 Thrombolytic Biosimilars
6.4.2.5 Fertility Biosimilars
6.5 Ranbaxy – Company Overview & Analysis
6.5.1 Ranbaxy Biosimilar Products
6.5.2 Ranbaxy Biosimilars Pipeline & Future Outlook
6.6 Reliance Life Sciences – Company Overview & Analysis
6.6.1 Reliance Life Sciences Biosimilar Products
6.6.2 Reliance Life Sciences Biosimilars Pipeline & Future Outlook
6.7 Intas Biopharmaceuticals – Company Overview & Analysis
6.7.1 Intas Biopharmaceuticals Biosimilar Products
6.7.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook
6.7.2.1 Biosimilar Pegylated Interferon
6.7.2.2 Biosimilar Etanercept
6.7.2.3 Biosimilar Ranibizumab
6.7.2.4 Overseas Opportunities
6.8 Other Indian Biosimilars Companies
6.8.1 Emcure Pharmaceuticals – Company Overview & Analysis
6.8.2 Shreya Life Sciences – Company Overview & Analysis
6.8.3 Cipla – Company Overview & Analysis
6.8.4 Shantha Biotechnics – Company Overview & Analysis
7. Leading Biosimilar Manufacturers in Latin America, 2016
7.1 Probiomed – Company Overview & Analysis
7.1.1 Probiomed Biosimilar Products
7.1.2 Probiomed Biosimilars Pipeline & Future Strategies
7.2 Biosidus – Company Overview & Analysis
7.2.1 Biosidus Biosimilar Products
7.2.2 Biosidus Biosimilars Pipeline & Future Strategies
7.3 Amega Biotech – Company Overview and Analysis
7.3.1 Amega – Biosimilar Products
7.3.2 Amega Biotech Biosimilars Pipeline & Future Strategies
7.4 Other Biosimilars Companies in South America
7.4.1 Bionovis – Company Overview & Analysis
7.4.2 Orygen Biotecnologia – Company Overview & Analysis
7.4.3 Recepta – Company Overview & Analysis
8. Leading Biosimilar Manufacturers in the Rest of the World, 2016
8.1 Celltrion – Company Overview & Analysis
8.1.1 Celltrion Biosimilar Products
8.1.2 Celltrion Biosimilars Pipeline & Future Strategies
8.1.2.1 Trastuzumab Biosimilar
8.1.2.2 Rituximab Biosimilar
8.1.2.3 Four Further Development mAb Biosimilar
8.2 LG Life Sciences – Company Overview & Analysis
8.2.1 LG Life Sciences Biosimilar Products
8.2.2 LG Life Science Biosimilars Pipeline & Future Strategies
8.3 Dong-A – Company Overview & Analysis
8.3.1 Dong-A Biosimilar Products
8.3.2 Dong-A Biosimilars Pipeline & Future Strategies
8.3.2.1 DA-3803 – hCG Biosimilar
8.3.2.2 DA-3031 – Pegylated Filgrastim Biosimilar
8.3.2.3 DA-3880 – Darbepoetin Alpha Biosimilar
8.3.2.4 DA-3111 – Trastuzumab Biosimilar
8.3.2.5 DA-3113 – Adalimumab Biosimilar
8.3.2.6 3853 – Etanercept Biosimilar
8.3.2.7 DA-3808 – Recombinant Factor VIII Biosimilar
8.4 Bioton – Company Overview & Analysis
8.4.1 Bioton’s Biosimilar Products
8.4.2 Bioton’s Biosimilars Pipeline & Future Strategies
8.5 Biocad – Company Overview & Analysis
8.5.1 Biocad’s Biosimilar Products
8.5.2 Biocad’s Biosimilars Pipeline & Future Strategies
8.6 Other Biosimilars Companies in the RoW
8.6.1 Gedeon-Richter – Company Overview & Analysis
8.6.2 Egis Pharmaceuticals – Company Overview & Analysis
8.6.3 JCR Pharmaceuticals – Company Overview & Analysis
8.6.4 Nippon Kayaku – Company Overview & Analysis
8.6.5 Fujifilm Kyowa Kirin Biologics – Company Overview & Analysis
8.6.6 Daiichi Sankyo – Company Overview & Analysis
9. Qualitative Analysis of Biosimilars Market, 2016-2026
9.1 SWOT Analysis of the Global Biosimilars Industry and Market, 2016-2026
9.1.1 Strengths
9.1.1.1 Savings in Healthcare Costs
9.1.1.2 Strong Pipeline – Innovation and Growth of the Biosimilars Market
9.1.1.3 Entry of Biosimilars Into the US market
9.1.2 Weaknesses
9.1.2.1 R&D Cost – Pricing Companies Out of Biosimilars?
9.1.2.2 Developing Market – Biosimilars Still Niche
9.1.2.3 Unclear Regulations for Biosimilars
9.1.3 Opportunities
9.1.3.1 Patent Expiry for Branded Biologics
9.1.3.2 Increase in Prevalence of Chronic Diseases
9.1.3.3 Innovation – New Technology Driving Biosimilar Growth
9.1.3.4 Focus on Biosimilar Monoclonal Antibodies and Insulin
9.1.4 Threats
9.1.4.1 Stricter Regulations for Biosimilar Manufacturers
9.1.4.2 Lawsuits – Patent Protection from Innovator Biologics
9.1.4.3 Biobetters – Removing the Need for Biosimilars?
9.2 STEP Analysis of the Global Biosimilars Industry and Market: 2016 -2026
9.2.1 Social Factors
9.2.1.1 Global Healthcare – An Ambitious Aim?
9.2.1.2 Raising Awareness will Lead to Greater Product Adoption
9.2.2 Technological Factors
9.2.2.1 Innovation Driven – Growing Manufacturing Efficiency
9.2.2.2 High Technological Expertise Needed
9.2.3 Economic Factors
9.2.3.1 R&D for Biosimilar Development – Cost Barriers
9.2.3.2 Healthcare Savings – Cutting Spending and Costs
9.2.4 Political Factors
9.2.4.1 Government Influence – Funding for Biosimilar Industry?
9.2.4.2 International Cooperation Required
9.2.4.3 Regularly Updated Guideline Will Benefit Developers
10. Research Interviews
10.1 Mr Chandru Chawla, Head of Corporate Strategy, Cipla
10.1.1 Cipla Overview
10.1.2 Introducing Cipla’s Biosimilars Landscape
10.1.3 Cipla’s Biosimilars Strategy: Collaboration & Competition
10.1.4 Future Directions for the Biosimilars Industry
10.2 Mr Peter Keller, Chief Business Officer, Selecta Bioscience
10.2.1 Novel Technology Platform
10.2.2 Application with Drugs
10.2.3 Biosimilar Vaccines – Future Potential?
10.2.4 Future Strategies
10.2.5 Biosimilar Market Outlook
10.3 Industry Source from a Leading Indian Biopharmaceutical Company
10.3.1 Indian Pharmaceutical and Biosimilars Market Overview
10.3.2 Indian Patent Protection – Effect on Biosimilar Industry
10.3.3 Partnerships among Biosimilar Companies
10.3.4 Future Developments in the Indian Biosimilars Market
11. Conclusions
11.1 Market Leaders Among Biosimilar Manufacturers
11.2 Will Sandoz Retain its Position as Market Leader?
11.3 Which Companies Are Best Placed to Lead in Future?
11.4 Big Pharma Companies Will Try Gain Market Entry
11.5 Contribution of Chinese and Indian Companies will Grow
11.6 Strong R&D Pipeline – Driver for Growth
11.7 Concluding Remarks
【レポート販売概要】
■ タイトル：世界のトップ25バイオシミラー（バイオ後続品）メーカー分析2016-2026■ 英文：Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026
■ 発行日：2016年4月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041543
■ 調査対象地域：グローバル
- 付加製造（積層造形法）技術及び材料の世界市場：ステレオ・リソグラフィー、ポリジェット印刷、結合剤噴射印刷、レーザー焼結、3Dプリンティング等The additive manufacturing market report analyzes the market by technology, material, application, and geography. The technology segment comprises Stereo lithography (SLA), Binder-Jetting, Poly-Jet, Laser Sintering, Electron Beam Melting (EBM), Fused Disposition Modeling (FDM), Laminated Object Manufacturing (LOM), Three Dimensional Inkjet Printing (3DP), and other proprietary technologies. The gl …
- パルプの世界市場：木材パルプ、化学パルプ、機械パルプ、非木材パルプAbout the Pulp Market Pulp is a type of fibrous material that is largely composed of water, cellulose fibers, lignin, and hemicelluloses. Cellulose fibers are essential for the production of paper, while lignin is a type of polymer that binds these fibers together. Hemicellulose, like cellulose, is a carbohydrate-based polymer that binds closely to cellulose fibers and along with cellulose fibers, …
- 組込みディスプレイの世界市場：LCD、LED、OLEDThe usage of embedded displays in devices such as treadmill, microwave, or insulin pump or front loader, we have witnessed a huge growth in the market and in the near future, the market for these devices is expected to overcome the global population size. Increase in the automated devices has increased the demand of embedded displays. Embedded displays today are advanced enough to be applied in hi …
- 薄膜太陽電池モジュール市場2013Thin-film Solar Module Market Analysis, 2013 - First Solar, the Undisputed Leader Summary Global thin-film solar module production capacity grew at a CAGR of 29% from 1,858 MW in 2008 to 6,568 MW by the year end 2013. However, demand for thin-film solar modules did not surge as significantly as the growth in thin-film module production capacity which resulted in higher overcapacity rate of 105% in …
- 世界のフラッキング化学物質及びフラッキング液体市場動向及び予測The global fracking (hydraulic fracturing) fluids market is likely to witness a CAGR of 9.6% from 2013 to 2018. North America is the largest market for fracking fluids and chemicals, followed by Asia-Pacific, Latin America, Europe, the Middle East and Africa. The fracking fluids market includes the major types of fluid base used such as Water-based, Gelled Oil-based, and Foam-based. The fracking c …
- Indian Pharmaceutical Market Outlook – Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investmentIndian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment Summary GBI Research’s new report “Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment” provides in-depth analysis of the trends, issues …
- 太陽光発電用マイクロインバータ―（ソーラーマイクロインバータ―）の世界市場2018-2022About Solar Microinverter Solar microinverters convert direct current (DC) from solar panels into alternate current (AC) of the required frequency. The output from several microinverters is later combined and fed to electrical grids to generate power. Technavio’s analysts forecast the global solar microinverter market to grow at a CAGR of 15.54% during the period 2018-2022. Covered in this report …
- ブラジルの心臓血管外科用機器市場見通し（～2021）Brazil Cardiovascular Surgery Outlook to 2021 Summary GlobalData’s new report, "Brazil Cardiovascular Surgery Outlook to 2021", provides key procedures data on the Brazil Cardiovascular Surgery. The report provides procedure volumes within market segments - Coronary Artery Bypass Graft (CABG) Procedures and Isolated Valve Procedures. The data in the report is derived from dynamic market forecast m …
- BRIC（ブラジル/ロシア/インド/中国）の原子力発電市場About Nuclear Power Nuclear power in BRIC countries is expected to experience moderate growth during the period 2014-2018. The cumulative installed capacity for nuclear power in BRIC countries was 47.8 GW in 2013, Russia being the leading country among BRIC nations, with cumulative installed capacity of 25.2 GW. China is expected to have the maximum capacity additions in the forecast period and wi …
- ポリエーテルアミンの世界市場予測（～2022年）：モノアミン、ジアミン、トリアミンThe global polyetheramine market is projected to reach USD 1,074.0 Million by 2022, at a CAGR of 9.3% from 2017 to 2022. The growing use of polyetheramine in different applications such as epoxy coatings, composites, polyurea, and adhesives & sealants for construction and wind energy industry is driving the market for polyetheramine. The use of polyetheramine-based composites in the wind energy in …
- 産業用エネルギー管理システムの世界市場：エネルギー管理ソフトウェア/装置/サービスAbout Energy Management System in Industrial Sector Energy management system for the Industrial sector is a system of computer-aided tools that help industries to monitor, control, and optimize their electrical loads. Energy management trend is shifting from hardware-based solutions to extensive software, hardware, and service-based solutions. This is achieved through a holistic view into the ener …
- Brownstone Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- 2012Brownstone Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Brownstone Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- Zargon Oil & Gas Ltd：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Zargon Oil & Gas Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Zargon Oil & Gas Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- 世界の血液分析器市場動向（2012-2016）TechNavio's analysts forecast the Global Hematology Analyzers market to grow at a CAGR of 3.59 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Hematology Analyzers market has also been witnessing the consolidation of the Industrial sector. However, the high cost of hematology analyzers could pose a challeng …
- Ambu A/S：市場シェア分析Ambu A/S Market Share Analysis Summary GlobalData’s new report, “Ambu A/S Market Share Analysis” provides in-depth information on Ambu A/S’s market position in the different medical equipment markets it operates in. The report provides Ambu A/S market share information in four key market categories – Patient Monitoring Accessories, Airway and Anesthesia Devices, Respiratory Devices and Respiratory …
